These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-001212-44 Letrozole adjuvant therapy duration (LEAD)study: standard versus long treatment. A phase III study in postmenopausal women with early breast cancer not-yet-due
Ongoing 2005-001213-18 Letrozole adjuvant therapy after tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patients not-yet-due
Completed, but no date 2005-005548-21 Phase I-II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Erlotinib (EGFR TKI) plus Oxaliplatin and Capecitabine (XELOX) in Patients with Metastatic Colorectal Cancer: XELOX-TARAV study bad-data
Completed, but no date 2007-005977-67 SUNITINIB EITHER BEFORE OR AFTER CYTOREDUCTIVE NEPHRECTOMY A PHASE II TRIAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA bad-data
Ongoing 2007-006031-30 A Randomized Trial with factorial Design comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in metastatic breast cancer progressing after Aromatase Inhibitor therapy not-yet-due
Ongoing 2008-000486-29 A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer not-yet-due
Ongoing 2008-006798-33 Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENES... not-yet-due
Ongoing 2013-003194-10 A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Bre... not-yet-due
Ongoing 2013-005044-29 A randomised, multicentre, open-label Phase II trial investigating activity of chemotherapy and lapatinib and Trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) refractory to an... not-yet-due
Ongoing 2014-003798-41 Randomized phase III study of fulvestrant as maintenance therapy after first-line chemotherapy in HER2 negative postmenopausal metastatic breast cancer patients not-yet-due
Ongoing 2014-004035-38 Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopausal ... not-yet-due
Ongoing 2015-000194-12 Isoquercetin as an adjunct therapy in patients with kidney cancer receiving first-line sunitinib: a phase I/II trial not-yet-due